Vascular protection with cilazapril

J. P. Clozel, Jerry S Powell, H. Kuhn, R. K M Muller, F. Hefti, H. R. Baumgartner

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The hypertrophy of the media of coronary arteries associated with hypertension reduces cross-sectional area and limits vascular reserve. Cilazapril 10 mg/kg daily decreased cardiac hypertrophy, and decreased minimal coronary vascular resistance by 40% when administered to spontaneously hypertensive rats (SHR) at the onset of hypertension. After hypertension had developed, cilazapril restored arterial pressure to normal and increased the maximal coronary blood flow in isolated perfused hearts by 96%, which was probably a result of a marked decrease in medial hypertrophy of the coronary arteries. Similarly, cilazapril improved cerebral vascular reserve in the mesenteric and renal arteries of SHR. In the rat model of vascular injury produced by ballooning, cilazapril 10 mg/kg daily demonstrated a marked preventive effect on the myointimal proliferation that resulted in untreated controls, a phenomenon responsible for restenosis in humans after arterial angioplasty. Although this effect occurred with usual antihypertensive dosages in rats, it appeared to be independent of the decrease in arterial pressure since effective antihypertensive dosages of verapamil did not prevent neointima formation. In view of the clinical potential for preventing restenosis after coronary angioplasty, 2 multicentre trials of cilazapril are ongoing to test this hypothesis.

Original languageEnglish (US)
Pages (from-to)62-67
Number of pages6
JournalDrugs
Volume41
Issue numberSUPPL. 1
StatePublished - 1991
Externally publishedYes

Fingerprint

Cilazapril
Blood Vessels
Rats
Inbred SHR Rats
Hypertension
Angioplasty
Hypertrophy
Antihypertensive Agents
Coronary Vessels
Arterial Pressure
Coronary Restenosis
Neointima
Mesenteric Arteries
Vascular System Injuries
Cardiomegaly
Renal Artery
Verapamil
Vascular Resistance
Multicenter Studies
Blood

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Clozel, J. P., Powell, J. S., Kuhn, H., Muller, R. K. M., Hefti, F., & Baumgartner, H. R. (1991). Vascular protection with cilazapril. Drugs, 41(SUPPL. 1), 62-67.

Vascular protection with cilazapril. / Clozel, J. P.; Powell, Jerry S; Kuhn, H.; Muller, R. K M; Hefti, F.; Baumgartner, H. R.

In: Drugs, Vol. 41, No. SUPPL. 1, 1991, p. 62-67.

Research output: Contribution to journalArticle

Clozel, JP, Powell, JS, Kuhn, H, Muller, RKM, Hefti, F & Baumgartner, HR 1991, 'Vascular protection with cilazapril', Drugs, vol. 41, no. SUPPL. 1, pp. 62-67.
Clozel JP, Powell JS, Kuhn H, Muller RKM, Hefti F, Baumgartner HR. Vascular protection with cilazapril. Drugs. 1991;41(SUPPL. 1):62-67.
Clozel, J. P. ; Powell, Jerry S ; Kuhn, H. ; Muller, R. K M ; Hefti, F. ; Baumgartner, H. R. / Vascular protection with cilazapril. In: Drugs. 1991 ; Vol. 41, No. SUPPL. 1. pp. 62-67.
@article{ccecbcb268014eacafbed5441c81da75,
title = "Vascular protection with cilazapril",
abstract = "The hypertrophy of the media of coronary arteries associated with hypertension reduces cross-sectional area and limits vascular reserve. Cilazapril 10 mg/kg daily decreased cardiac hypertrophy, and decreased minimal coronary vascular resistance by 40{\%} when administered to spontaneously hypertensive rats (SHR) at the onset of hypertension. After hypertension had developed, cilazapril restored arterial pressure to normal and increased the maximal coronary blood flow in isolated perfused hearts by 96{\%}, which was probably a result of a marked decrease in medial hypertrophy of the coronary arteries. Similarly, cilazapril improved cerebral vascular reserve in the mesenteric and renal arteries of SHR. In the rat model of vascular injury produced by ballooning, cilazapril 10 mg/kg daily demonstrated a marked preventive effect on the myointimal proliferation that resulted in untreated controls, a phenomenon responsible for restenosis in humans after arterial angioplasty. Although this effect occurred with usual antihypertensive dosages in rats, it appeared to be independent of the decrease in arterial pressure since effective antihypertensive dosages of verapamil did not prevent neointima formation. In view of the clinical potential for preventing restenosis after coronary angioplasty, 2 multicentre trials of cilazapril are ongoing to test this hypothesis.",
author = "Clozel, {J. P.} and Powell, {Jerry S} and H. Kuhn and Muller, {R. K M} and F. Hefti and Baumgartner, {H. R.}",
year = "1991",
language = "English (US)",
volume = "41",
pages = "62--67",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Vascular protection with cilazapril

AU - Clozel, J. P.

AU - Powell, Jerry S

AU - Kuhn, H.

AU - Muller, R. K M

AU - Hefti, F.

AU - Baumgartner, H. R.

PY - 1991

Y1 - 1991

N2 - The hypertrophy of the media of coronary arteries associated with hypertension reduces cross-sectional area and limits vascular reserve. Cilazapril 10 mg/kg daily decreased cardiac hypertrophy, and decreased minimal coronary vascular resistance by 40% when administered to spontaneously hypertensive rats (SHR) at the onset of hypertension. After hypertension had developed, cilazapril restored arterial pressure to normal and increased the maximal coronary blood flow in isolated perfused hearts by 96%, which was probably a result of a marked decrease in medial hypertrophy of the coronary arteries. Similarly, cilazapril improved cerebral vascular reserve in the mesenteric and renal arteries of SHR. In the rat model of vascular injury produced by ballooning, cilazapril 10 mg/kg daily demonstrated a marked preventive effect on the myointimal proliferation that resulted in untreated controls, a phenomenon responsible for restenosis in humans after arterial angioplasty. Although this effect occurred with usual antihypertensive dosages in rats, it appeared to be independent of the decrease in arterial pressure since effective antihypertensive dosages of verapamil did not prevent neointima formation. In view of the clinical potential for preventing restenosis after coronary angioplasty, 2 multicentre trials of cilazapril are ongoing to test this hypothesis.

AB - The hypertrophy of the media of coronary arteries associated with hypertension reduces cross-sectional area and limits vascular reserve. Cilazapril 10 mg/kg daily decreased cardiac hypertrophy, and decreased minimal coronary vascular resistance by 40% when administered to spontaneously hypertensive rats (SHR) at the onset of hypertension. After hypertension had developed, cilazapril restored arterial pressure to normal and increased the maximal coronary blood flow in isolated perfused hearts by 96%, which was probably a result of a marked decrease in medial hypertrophy of the coronary arteries. Similarly, cilazapril improved cerebral vascular reserve in the mesenteric and renal arteries of SHR. In the rat model of vascular injury produced by ballooning, cilazapril 10 mg/kg daily demonstrated a marked preventive effect on the myointimal proliferation that resulted in untreated controls, a phenomenon responsible for restenosis in humans after arterial angioplasty. Although this effect occurred with usual antihypertensive dosages in rats, it appeared to be independent of the decrease in arterial pressure since effective antihypertensive dosages of verapamil did not prevent neointima formation. In view of the clinical potential for preventing restenosis after coronary angioplasty, 2 multicentre trials of cilazapril are ongoing to test this hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=0026096526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026096526&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 62

EP - 67

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - SUPPL. 1

ER -